On Thursday, September 28, an FDA Advisory Committee will review ataluren for potential approval and use within our Duchenne community.
The Duchenne community is joining forces in a show of strength to demonstrate to the FDA our community’s support for our robust therapeutic pipeline. This is our community’s opportunity to once again stand up and share our stories and our experiences with a therapy we believe is safe and effective.
While many of you may be attending in person or even participating, we know that those of you unable to attend are curious as to how the process will unfold throughout the day. See below for information on how you can follow along from home.
Watch a live stream of the Ad Comm
The Center for Drug Evaluation and Research (CDER) plans to provide a free of charge, live webcast of the September 28, 2017, meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. Please note that the webcast will not display until the meeting begins at approximately 9:00 a.m. EST on September 28, 2017. While CDER is making a webcast available to the public for this meeting, there may be instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible. CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available. The meeting webcast can be accessed at the following web address: http://fda.yorkcast.com/webcast/Play/734c628502b84ae2baedc5fa6c5db5...
(click here to view the official webcast notice from FDA)
For more information about the FDA Ad Comms, please visit the links and resources that we at PPMD have compiled with the assistance of our community members, regulatory advisors, and federal agency partners: